The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.
Activity-based ubiquitin-specific protease (USP) profiling of virus-infected and malignant human cells
Open accessAbstract
The family of ubiquitin (Ub)-specific proteases (USP) removes Ub from Ub conjugates and regulates a variety of cellular processes. The human genome contains many putative USP-encoding genes, but little is known about USP tissue distribution, pattern of expression, activity, and substrate specificity. We have used a chemistry-based functional proteomics approach to identify active USPs in normal, virus-infected, and tumor-derived human cells. Depending on tissue origin and stage of activation/differentiation, different USP activity profiles were revealed. The activity of specific USPs, including USP5, -7, -9, -13, -15, and -22, was up-regulated by mitogen activation or virus infection in normal T and B lymphocytes. UCH-L1 was highly expressed in tumor cell lines of epithelial and hematopoietic cell origin but was not detected in freshly isolated and mitogen-activated cells. Up-regulation of this USP was a late event in the establishment of Epstein–Barr virus-immortalized lymphoblastoid cell lines and correlated with enhanced proliferation, suggesting a possible role in growth transformation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Unique DUB activity was additionally identified following EBV establishment of latency and correlated with changes in cell proliferation rates.”
From The Impact of Mass Spectrometry–Based Proteomics on Fundamental Discoveries in Virology (2014) · cites this paper as [145]
In the citing paper
“By using AP of active DUBs and MS analysis, the activities of several DUBs were found to be strongly upregulated in EBV-infected lymphocytes (145).”
From The Impact of Mass Spectrometry–Based Proteomics on Fundamental Discoveries in Virology (2014) · cites this paper as [145]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Ubiquitin-Proteasome Proteolytic Pathway: Destruction for the Sake of Construction
Glickman, M. H., & Ciechanover, A. J. (2002) · Physiological Reviews · doi:10.1152/physrev.00027.2001 · Cited by 4,304
Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization
Li, M., Chen, D., Shiloh, A., Luo, J., Nikolaev, A. Y., Qin, J., & Gu, W. J. (2002) · Nature · doi:10.1038/nature737 · Cited by 1,048
The tumour suppressor CYLD negatively regulates NF-κB signalling by deubiquitination
Kovalenko, A., Chable-Bessia, C., Cantarella, G., Israël, A., Wallach, D., & Courtois, G. (2003) · Nature · doi:10.1038/nature01802 · Cited by 1,018
CYLD is a deubiquitinating enzyme that negatively regulates NF-κB activation by TNFR family members
Trompouki, E., Hatzivassiliou, E., Tsichritzis, T., Farmer, H., Ashworth, A., & Mosialos, G. (2003) · Nature · doi:10.1038/nature01803 · Cited by 964
Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-κB
Brummelkamp, T. R., Nijman, S. M. B., Dirac, A. M. G., & Bernards, R. (2003) · Nature · doi:10.1038/nature01811 · Cited by 947
The Neuron-Specific Protein PGP 9.5 Is a Ubiquitin Carboxyl-Terminal Hydrolase
Wilkinson, K. D., Lee, K., Deshpande, S. S., Duerksen-Hughes, P. J., Boss, J. M., & Pohl, J. (1989) · Science · doi:10.1126/science.2530630 · Cited by 871
Liu, Y., Fallon, L., Lashuel, H. A., Liu, Z., & Lansbury, P. T. (2002) · Cell · doi:10.1016/s0092-8674(02)01012-7 · Cited by 786
A cryptic protease couples deubiquitination and degradation by the proteasome
Yao, T., & Cohen, R. E. (2002) · Nature · doi:10.1038/nature01071 · Cited by 727
Jensen, D. E., Proctor, M. L., Marquis, S. T., Gardner, H. P., Ha, S. I., Chodosh, L. A., Ishov, A. M., Tommerup, N., Vissing, H., Sekido, Y., et al. (1998) · Oncogene · doi:10.1038/sj.onc.1201861 · Cited by 725
Chemistry-Based Functional Proteomics Reveals Novel Members of the Deubiquitinating Enzyme Family
Borodovsky, A., Ovaa, H., Kolli, N., Gan-Erdene, T., Wilkinson, K. D., Ploegh, H. L., & Kessler, B. M. (2002) · Chemistry & Biology · doi:10.1016/s1074-5521(02)00248-x · Cited by 588
Self-citation
Research works printed but not linked: 10
- Gray, D. A., Inazawa, J., Gupta, K., Wong, A., Ueda, R. & Takahashi, T. (1995) Oncogene 10, 2179–2183.7784062
- D'Andrea, V., Malinovsky, L., Berni, A., Biancari, F., Biassoni, L., Di Matteo, F. M., Corbellini, L., Falvo, L., Santoni, F., Spyrou, M. & De Antoni, E. (1997) G Chir 18, 521–524.9435142
- Tezel, E., Hibi, K., Nagasaka, T. & Nakao, A. (2000) Clin. Cancer Res. 6, 4764–4767.11156232
- Brichory, F., Beer, D., Le Naour, F., Giordano, T. & Hanash, S. (2001) Cancer Res. 61, 7908–7912.11691811
- Kieff, E. (1996) in Fields Virology, eds. Fields, B. N., Knipe, D. M. & Howley, P. M. (Lippincott, Raven, Philadelphia), Vol. 2, 3rd Ed., pp. 2343–2396.
- Finch, J. S., St. John, T., Krieg, P., Bonham, K., Smith, H. T., Fried, V. A. & Bowden, G. T. (1992) Cell Growth Differ. 3, 269–278.1321656
- Fischer-Vize, J. A., Rubin, G. M. & Lehmann, R. (1992) Development (Cambridge, U.K.) 116, 985–1000.
- Scheper, R. J., Broxterman, H. J., Scheffer, G. L., Kaaijk, P., Dalton, W. S., van Heijningen, T. H., van Kalken, C. K., Slovak, M. L., de Vries, E. G., van der Valk, P., et al. (1993) Cancer Res. 53, 1475–1479.7680954
- Filipits, M., Jaeger, U., Simonitsch, I., Chizzali-Bonfadin, C., Heinzl, H. & Pirker, R. (2000) Clin. Cancer Res. 6, 3417–3423.10999723
- Filipits, M., Drach, J., Pohl, G., Schuster, J., Stranzl, T., Ackermann, J., Konigsberg, R., Kaufmann, H., Gisslinger, H., Huber, H., et al. (1999) Clin. Cancer Res. 5, 2426–2430.10499614
Cited by
Sorted by citations
Deubiquitylating enzymes and drug discovery: emerging opportunities
Harrigan, J. A., Jacq, X., Martin, N. M., & Jackson, S. P. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.152 · Cited by 940
Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
Chen, D., Frezza, M., Schmitt, S. M., Kanwar, J., & Dou, Q. P. (2011) · Current Cancer Drug Targets · doi:10.2174/156800911794519752 · Cited by 810
Mechanism-Based Profiling of Enzyme Families
Evans, M. J., & Cravatt, B. F. (2006) · Chemical Reviews · doi:10.1021/cr050288g · Cited by 574
Activity-Based Chemical Proteomics Accelerates Inhibitor Development for Deubiquitylating Enzymes
Altun, M., Kramer, H., Willems, L. I., McDermott, J. L., Leach, C. A., Goldenberg, S. J., Kumar, S., Konietzny, R., Fischer, R., Kogan, E., et al. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.08.018 · Cited by 415
Self-citationKapuria, V., Peterson, L. F., Fang, D., Bornmann, W. G., Talpaz, M., & Donato, N. J. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1530 · Cited by 383
Metadata
- Authors
- Ovaa, H., Kessler, B. M., Rolén, U., Galardy, P. J., Ploegh, H. L., & Masucci, M. G.
- Affiliations
- Harvard University (US)
- Corresponding author
- Masucci, Maria G.
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2004-02-11
- Volume
- 101
- Issue
- 8
- Pages
- 2253-2258
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC356937
- OpenAlex
- W2130935241
- Cited by
- 190
- References
- 49
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 2 · 2023: 6 · 2022: 8 · 2021: 5 · 2020: 5 · 2019: 11 · 2018: 7 · 2017: 6 · 2016: 8 · 2015: 7 · 2014: 13 · 2013: 7 · 2012: 9
- FWCI
- 4.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Multiple Myeloma Research Foundation
- Stiftelsen för Strategisk Forskning
- Cancerfonden
- Karolinska Institutet
- National Institutes of Health
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
- Keywords
- ubiquitin-specific protease, deubiquitination, virus-infected cells, cancer cell lines, Epstein-Barr virus, UCHL1, USP5, USP7, USP13, USP15, USP22, lymphocyte activation, mitogen stimulation, cell proliferation, growth transformation, functional proteomics
- MeSH terms
- Ubiquitin-Specific Peptidase 7, B-Lymphocytes, Cell Line, Humans, Endopeptidases, Mass Spectrometry, T-Lymphocytes, Ubiquitin Thiolesterase, Cell Line, Tumor, Ubiquitin-Specific Proteases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
